Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2007

View Archived Issues

DA-9102 improves atopic dermatitis in proof-of-concept trial

Eden Biodesign and Cancer Research UK sign development agreements for cancer drugs

Recent patents claim novel therapeutic agents for schizophrenia, depression and anxiety

Phoqus begins phase II trial of Chronocort for CAH

Novel ATP-sensitive potassium channel activators emerge from Janssen R&D

Recent Jerini patent imparts new therapeutic agents for ocular disorders

AMANET initiates clinical trial of malaria vaccine GMZ2 in Africa

InterMune's phase Ib amended CTA for ITMN-191 approved in Europe

Encysive completes patient enrollment of phase II trial of Thelin for DHF

Isis begins phase I trial of ISIS-325568 for type 2 diabetes

Septic shock treatment study questions guideline recommendations

Upregulation of ACE as a potential therapeutic strategy to reduce Abeta deposition in the AD brain

Promising preclinical results of intranasally delivered influenza A vaccine

Novel PET cardiac tracer profiled at BMS

MediGene completes patient recruitment for clinical trial of oncolytic virus

Ovation initiates U.S. phase III clobazam study in epilepsy

FDA fast tracks ATryn in antithrombin deficiency and allows rolling BLA submission

FDA grants fast track designation to AGI Dermatics' Dimericine for XP

Provectus to initiate phase II study of Provecta for metastatic melanoma

Icagen begins phase I study of ICA-105665 for epilepsy

USAN approves nonproprietary name adipiplon for Neurogen's NG2-73 for insomnia

Advanced Viral Research expects to begin phase II trial of AVR-118

Positive results for Clinical Data's pivotal phase III study of vilazodone for depression

Depomed reports results of phase IIa proof-of-concept study of omeprazole for GERD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...